Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh(®TM)) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer

This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the “Burden of Therapy” (BOTh(®TM)) in pancreatic ductal adenocarcinoma (PDAC). In the RASH study, 150 patients with newly diagnosed metastatic PDAC were treated with gemcitabine plus erlotinib (gem/erlotinib) f...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorman, Klara, Boeck, Stefan, Snijder, Robert J., Siveke, Jens T., Schenk, Michael, Mayerle, Julia, Caca, Karel, Freiberg-Richter, Jens, Fischer von Weikersthal, Ludwig, Kullmann, Frank, Reinacher-Schick, Anke, Fuchs, Martin, Kanzler, Stephan, Kunzmann, Volker, Ettrich, Thomas J., Zhang, Danmei, Held, Swantje, Abdul-Ahad, Ayad, von Bergwelt-Baildon, Michael, Heinemann, Volker, Haas, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297548/
https://www.ncbi.nlm.nih.gov/pubmed/37366919
http://dx.doi.org/10.3390/curroncol30060436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297548/
https://www.ncbi.nlm.nih.gov/pubmed/37366919
http://dx.doi.org/10.3390/curroncol30060436

Ejemplares similares